THP-NanoTarget

A Cheminformatics Framework for Leakage-Aware Benchmarking and Prioritization of Tumor-Homing Peptides

A public-data research dashboard integrating leakage-aware peptide sequence scoring, ensemble-based candidate prioritization, peptide ligand visualization, nanocarrier-ligand suitability, motif-supported receptor hypotheses, HPA-derived receptor–cancer targetability evidence, and validation summaries.

Ensemble sequence scoring

Peptide structure visualization

Bioactive hard-negative challenge

Full HPA receptor atlas: 54 receptors

Leakage-aware validation views

Research use only

Sequence scoring model

OOF TF-IDF k-mer logistic

AUROC: 0.7124
AUPRC: 0.6142
Use: exploratory candidate triage

Specificity-oriented model

OOF calibrated linear SVM

MCC: 0.2808
Use: specificity-oriented triage
Role: reduces over-prioritization of bioactive hard negatives

Data resources

Candidate-context matrix + HPA targetability atlas

Ligands: 1,401
Candidate-context rows: 21,452
Targetability rows: 1,671
HPA receptor targets: 54

Input peptide

Enter a canonical amino-acid peptide sequence. Structure rendering supports readable 2D display for peptides up to ~45 residues when RDKit is available.

Peptide sequence

Number of receptor–cancer contexts to display

3 30

Example peptide candidates

Run a peptide triage query to view the sequence score, ligand features, and context evidence.

Sequence-score model components

Prioritized receptor–cancer contexts

Conservative THP-like analog generator

Generate motif-aware peptide analogs from one or more seed sequences, then rank them using the sequence model score, motif-rule score, RDKit descriptor plausibility, nearest-neighbor novelty audit, and CancerPPD hard-negative similarity. This module supports computational analog exploration only; it does not validate new THPs.

Seed peptide sequence(s)

Maximum analogs per seed

20 300

Maximum substitutions per analog

1 3

Top ranked analogs to display

20 200

Generate motif-aware analogs to view conservative prioritization and novelty-audit results.

Generated analog score distribution

Nearest-positive novelty audit

Ranked generated analog candidates

Ranked generated analog candidates

Cheminformatics representation and similarity search

Explore RDKit-derived peptide descriptors, Morgan/ECFP chemical-space maps, Tanimoto nearest neighbors, and motif-rule baseline comparisons. These are computational representations generated from canonical peptide sequences, not experimental conformations or binding measurements.

Peptide sequence for descriptor and similarity search

Top-k chemically similar peptides

5 50

Query peptide RDKit descriptors

Query peptide RDKit descriptors

Morgan/ECFP nearest-neighbor plot

Nearest-neighbor similarity results

Nearest-neighbor similarity results

Chemical-space map

Descriptor distribution

Motif-rule baseline comparison

Motif-rule baseline table

Motif-rule baseline table

4202	1401	2801	0.15	0.7153	0.4694	0.6913	0.5721	0.3163	0.2106	0.6048	0.2141	MotifRuleBaseline_threshold_0p4	0.3754

Motif-rule baseline table

4202	1401	2801	0.4	0.632	0.4694	0.6913	0.5721	0.3163	0.2106	0.6048	0.2141	MotifRuleBaseline_threshold_0p4	null
4202	1401	2801	0.15	0.632	0.4694	0.6628	0.6184	0.4897	0.238	0.4942	0.4854	MotifRuleBaseline_best_MCC	null
4202	1401	2801	0.05	0.632	0.4694	0.3477	0.5066	0.5014	0.0397	0.3364	0.9836	MotifRuleBaseline_best_F1	null
4202	1401	2801	0.5	0.7153	0.6125	0.6299	0.6448	0.5541	0.2731	0.4631	0.6895	ensemble_rank_average	0.3754
4202	1401	2801	0.5	0.715	0.6122	0.7225	0.6376	0.479	0.3247	0.6404	0.3826	ensemble_equal_mean	0.3704
4202	1401	2801	0.5	0.7149	0.6124	0.7166	0.6413	0.4943	0.318	0.6101	0.4154	ensemble_discovery_weighted	0.3683
4202	1401	2801	0.5	0.7132	0.6051	0.7228	0.6206	0.4303	0.3157	0.6832	0.3141	ensemble_conservative_gated	0.3662
4202	1401	2801	0.5	0.7124	0.6142	0.6713	0.6482	0.5401	0.2878	0.5062	0.5789	ensemble_stacked_logistic	0.3669
4202	1401	2801	0.5	0.7103	0.5976	0.7016	0.6358	0.4948	0.2928	0.568	0.4383	count_logistic_2_4	0.359
4202	1401	2801	0.5	0.7079	0.5974	0.7013	0.6363	0.4962	0.2932	0.567	0.4411	tfidf_logistic_2_4	0.3369
4202	1401	2801	0.5	0.7043	0.5784	0.712	0.5826	0.3101	0.2808	0.7705	0.1941	tfidf_svm_2_4	0.3433
4202	1401	2801	0.5	0.7039	0.6155	0.7261	0.6344	0.4664	0.3298	0.6653	0.359	tfidf_logistic_3_5	0.3754

STRING physical PPI receptor-network layer

Explore receptor-level STRING physical PPI support and HPA+STRING receptor-priority context. This is network/module evidence only and is not peptide-receptor binding validation.

Protein-interaction / receptor-network status

Receptor PPI summary rows: 54
STRING/PPI edge rows: 17824
Source: STRING
PPI type: physical protein-protein links
Score threshold: combined_score >= 700 for high-confidence network support
Total edges scanned: 1477610
Receptor-associated edges kept: 17824
Mapped receptors: 54

Boundary: STRING/PPI support indicates network proximity and module coherence only. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, safety, or clinical actionability.

Number of receptors/edges to show

5 100

Minimum STRING combined score

0 1000

Interactive Protein-Protein Interaction Network (PPIN)

Receptor-level network support

High-confidence STRING/PPI edges

Displayed PPIN nodes

Displayed PPIN nodes

ANGPT1	18	17982	false	Hepatocyte growth factor receptor	immune checkpoint ligand / tumor immune marker	Tier 3: moderate/supportive candidate	null	68.1217	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.

Displayed PPIN nodes

EGFR	18	17982	false	Epidermal growth factor receptor	RTK / epithelial tumor receptor	Tier 1: strongest receptor candidate	10	100	2	2	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
ITGB1	8	7992	false	Integrin beta 1	integrin / adhesion receptor	Tier 2: strong receptor candidate	7.5	68.1217	2	2	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
FN1	6	5994	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
ITGB3	6	5994	false	Integrin beta 3	integrin / angiogenesis receptor	Tier 1: strongest receptor candidate	9	63.9366	2	2	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
CD274	4	3996	false	PD-L1	immune checkpoint ligand / tumor immune marker	Tier 3: moderate/supportive candidate	5.75	38.7883	0.5	0.5	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
ERBB2	4	3996	false	HER2	RTK / epithelial tumor receptor	Tier 2: strong receptor candidate	8	65.4541	2	2	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
FLT1	4	3996	false	VEGFR1	angiogenic RTK	Tier 2: strong receptor candidate	8	56.5421	2	2	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
ITGAV	4	3996	false	Integrin alpha V	integrin / angiogenesis receptor	Tier 1: strongest receptor candidate	10	92.8177	2	2	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
PLAUR	4	3996	false	uPAR	protease-associated invasion receptor	Tier 2: strong receptor candidate	7.5	52.2039	1.5	1.5	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
TEK	4	3996	false	TIE2	angiopoietin receptor / vascular receptor	Tier 2: strong receptor candidate	7.5	56.1861	0.5	0.5	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
ERBB3	3	2997	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
ITGA5	3	2997	false	Integrin alpha 5	integrin / extracellular matrix receptor	Tier 2: strong receptor candidate	7	41.1448	2	2	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
NRP1	3	2997	false	Neuropilin 1	vascular / CendR pathway receptor	Tier 2: strong receptor candidate	9.5	76.0097	2	2	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
ALCAM	2	1998	false	ALCAM / CD166	cell adhesion receptor	Tier 2: strong receptor candidate	7	59.4017	0.5	0.5	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
ANGPT1	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
ANGPT2	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
APOE	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
AXL	2	1998	false	AXL receptor tyrosine kinase	RTK / EMT receptor	Tier 3: moderate/supportive candidate	5	35.8034	0.5	0.5	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
CBL	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
CD6	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
CD80	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
CXCL12	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
CXCL8	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
CXCR2	2	1998	false	CXCR2	chemokine receptor	Tier 2: strong receptor candidate	7	33.9552	2	2	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
CXCR4	2	1998	false	CXCR4	chemokine receptor	Tier 2: strong receptor candidate	7.5	54.6129	2	2	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
EGF	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
EPGN	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
EREG	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
GAS6	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
GRB2	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
HBEGF	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
HFE	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
HGF	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
ITGA2B	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
ITGA4	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
ITGA6	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
KDR	2	1998	false	VEGFR2	angiogenic RTK	Tier 2: strong receptor candidate	7.5	48.6003	2	2	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
LRP1	2	1998	false	LRP1	endocytic receptor	Tier 2: strong receptor candidate	7	57.3283	1	1	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
MET	2	1998	false	Hepatocyte growth factor receptor	RTK / invasion-metastasis receptor	Tier 1: strongest receptor candidate	11	87.2844	2	2	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
PDCD1	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
PGF	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
PLAU	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
PLXNA1	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
SLC3A2	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
SLC7A5	2	1998	false	LAT1	amino-acid transporter	Tier 2: strong receptor candidate	7.5	71.5197	0	0	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
TFRC	2	1998	false	Transferrin receptor 1	nutrient uptake receptor	Tier 2: strong receptor candidate	8.5	76.7897	0.5	0.5	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
TGFA	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
VEGFB	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
VEGFC	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
VTN	2	1998	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
ERBB4	1	999	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
ILK	1	999	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
PDGFB	1	999	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
PDGFRB	1	999	false	PDGFR beta	stromal / vascular RTK receptor	Tier 2: strong receptor candidate	7.5	48.4302	2	2	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.
PLXNA2	1	999	false				null	null	null	null	Displayed STRING physical PPI node; network/module context only, not peptide-receptor binding evidence.

Displayed PPIN edges

Displayed PPIN edges

PDGFRB	PLXNA1	999	SLC7A5 — SLC3A2	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.

Displayed PPIN edges

EGFR	CBL	999	EGFR — CBL	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ITGB1	ITGA6	999	ITGB1 — ITGA6	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
NRP1	PLXNA1	999	NRP1 — PLXNA1	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
CD274	CD80	999	CD274 — CD80	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
KDR	VEGFC	999	KDR — VEGFC	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
KDR	VEGFC	999	KDR — VEGFC	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
EGFR	HBEGF	999	EGFR — HBEGF	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
LRP1	APOE	999	LRP1 — APOE	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
EGFR	EREG	999	EGFR — EREG	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
AXL	GAS6	999	AXL — GAS6	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
MET	HGF	999	MET — HGF	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
CD274	PDCD1	999	CD274 — PDCD1	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
TEK	ANGPT2	999	TEK — ANGPT2	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
FLT1	VEGFB	999	FLT1 — VEGFB	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
MET	HGF	999	MET — HGF	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
PLAUR	PLAU	999	PLAUR — PLAU	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ITGAV	FN1	999	ITGAV — FN1	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ITGB1	FN1	999	ITGB1 — FN1	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
PLAUR	VTN	999	PLAUR — VTN	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ERBB2	ERBB4	999	ERBB2 — ERBB4	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
FLT1	VEGFB	999	FLT1 — VEGFB	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ITGB3	ITGA2B	999	ITGB3 — ITGA2B	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
EGFR	EPGN	999	EGFR — EPGN	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ITGB1	ITGA4	999	ITGB1 — ITGA4	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ERBB2	EGFR	999	ERBB2 — EGFR	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ITGA5	ITGB1	999	ITGA5 — ITGB1	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
FLT1	PGF	999	FLT1 — PGF	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
CXCR4	CXCL12	999	CXCR4 — CXCL12	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
NRP1	PLXNA2	999	NRP1 — PLXNA2	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
EGFR	EGF	999	EGFR — EGF	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ERBB2	ERBB3	999	ERBB2 — ERBB3	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
EGFR	ERBB3	999	EGFR — ERBB3	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ITGB3	FN1	999	ITGB3 — FN1	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
CXCR2	CXCL8	999	CXCR2 — CXCL8	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ITGA5	FN1	999	ITGA5 — FN1	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
AXL	GAS6	999	AXL — GAS6	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
EGFR	TGFA	999	EGFR — TGFA	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ALCAM	CD6	999	ALCAM — CD6	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
TEK	ANGPT2	999	TEK — ANGPT2	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
EGFR	EGF	999	EGFR — EGF	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
PDGFRB	PDGFB	999	PDGFRB — PDGFB	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ALCAM	CD6	999	ALCAM — CD6	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
CXCR2	CXCL8	999	CXCR2 — CXCL8	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
PLAUR	VTN	999	PLAUR — VTN	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
EGFR	TGFA	999	EGFR — TGFA	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
EGFR	EREG	999	EGFR — EREG	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
SLC7A5	SLC3A2	999	SLC7A5 — SLC3A2	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ITGAV	FN1	999	ITGAV — FN1	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ITGB1	ILK	999	ITGB1 — ILK	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
TEK	ANGPT1	999	TEK — ANGPT1	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
EGFR	HBEGF	999	EGFR — HBEGF	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
CXCR4	CXCL12	999	CXCR4 — CXCL12	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ITGB3	ITGAV	999	ITGB3 — ITGAV	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
FLT1	PGF	999	FLT1 — PGF	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ITGB3	ITGA2B	999	ITGB3 — ITGA2B	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
EGFR	ERBB3	999	EGFR — ERBB3	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
TFRC	HFE	999	TFRC — HFE	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
EGFR	CBL	999	EGFR — CBL	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
EGFR	GRB2	999	EGFR — GRB2	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ITGB1	ITGA5	999	ITGB1 — ITGA5	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ITGB3	FN1	999	ITGB3 — FN1	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
EGFR	GRB2	999	EGFR — GRB2	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
EGFR	ERBB2	999	EGFR — ERBB2	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ITGAV	ITGB3	999	ITGAV — ITGB3	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
EGFR	EPGN	999	EGFR — EPGN	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
NRP1	PLXNA1	999	NRP1 — PLXNA1	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
SLC7A5	SLC3A2	999	SLC7A5 — SLC3A2	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
PLAUR	PLAU	999	PLAUR — PLAU	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
CD274	PDCD1	999	CD274 — PDCD1	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
CD274	CD80	999	CD274 — CD80	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ITGB1	ITGA4	999	ITGB1 — ITGA4	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
TFRC	HFE	999	TFRC — HFE	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
TEK	ANGPT1	999	TEK — ANGPT1	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
LRP1	APOE	999	LRP1 — APOE	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.
ITGB1	ITGA6	999	ITGB1 — ITGA6	STRING physical PPI edge; network/module context only, not peptide-receptor binding evidence.


CEACAM5	CEACAM5	Hepatocyte growth factor receptor	angiopoietin receptor / vascular receptor	Tier 1: strongest receptor candidate	9.5	0.5	0.5	0	6	moderate_high	HER2-binding peptides, affibody-like ligands	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.


MET	MET	Hepatocyte growth factor receptor	RTK / invasion-metastasis receptor	Tier 1: strongest receptor candidate	11	2	2	6	high	MET-binding peptides, HGF-inspired ligands	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
EGFR	EGFR	Epidermal growth factor receptor	RTK / epithelial tumor receptor	Tier 1: strongest receptor candidate	10	2	2	6	high	EGFR-binding peptides, GE11-like ligands	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
ITGAV	ITGAV	Integrin alpha V	integrin / angiogenesis receptor	Tier 1: strongest receptor candidate	10	2	2	6	very_high	RGD, cyclic RGD, iRGD-related targeting	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
NRP2	NRP2	Neuropilin 2	vascular / lymphangiogenesis receptor	Tier 1: strongest receptor candidate	10	2	2	6	high	CendR-like peptides	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
EPCAM	EPCAM	Epithelial cell adhesion molecule	epithelial tumor antigen	Tier 1: strongest receptor candidate	9.5	2	2	6	high	EpCAM-binding peptides	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
MUC1	MUC1	Mucin 1	mucin / epithelial tumor antigen	Tier 1: strongest receptor candidate	9.5	2	2	6	high	MUC1-binding peptides	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
NRP1	NRP1	Neuropilin 1	vascular / CendR pathway receptor	Tier 2: strong receptor candidate	9.5	2	2	5	very_high	iRGD, CendR peptides	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
CD44	CD44	CD44	hyaluronan receptor / stemness marker	Tier 2: strong receptor candidate	9.5	2	2	5	very_high	hyaluronic acid and CD44-binding peptides	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
CD276	CD276	B7-H3 / CD276	immune-modulatory tumor antigen	Tier 1: strongest receptor candidate	9.5	0.5	0.5	6	high	B7-H3-targeted ligands	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
ITGB3	ITGB3	Integrin beta 3	integrin / angiogenesis receptor	Tier 1: strongest receptor candidate	9	2	2	6	very_high	RGD, cyclic RGD	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
ITGB5	ITGB5	Integrin beta 5	integrin / angiogenesis receptor	Tier 2: strong receptor candidate	9	2	2	5	high	RGD-like peptides	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
NCL	NCL	Nucleolin	tumor cell-surface nucleolin	Tier 2: strong receptor candidate	9	1.5	1.5	5	very_high	F3 peptide, nucleolin-binding peptides	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
TFRC	TFRC	Transferrin receptor 1	nutrient uptake receptor	Tier 2: strong receptor candidate	8.5	0.5	0.5	6	very_high	transferrin and T7-like targeting	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
CDH3	CDH3	P-cadherin	cell adhesion receptor	Tier 2: strong receptor candidate	8.5	0.5	0.5	6	moderate	cadherin-associated targeting	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
FAP	FAP	Fibroblast activation protein	CAF / stromal protease	Tier 2: strong receptor candidate	8.5	0	0	5	very_high	FAP-targeted peptides	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
FLT1	FLT1	VEGFR1	angiogenic RTK	Tier 2: strong receptor candidate	8	2	2	6	moderate_high	VEGF-related targeting ligands	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
VCAM1	VCAM1	VCAM1	vascular adhesion receptor	Tier 2: strong receptor candidate	8	2	2	6	moderate_high	VCAM1-binding peptides	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
ERBB2	ERBB2	HER2	RTK / epithelial tumor receptor	Tier 2: strong receptor candidate	8	2	2	5	high	HER2-binding peptides, affibody-like ligands	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
SLC2A1	SLC2A1	GLUT1	glucose transporter	Tier 2: strong receptor candidate	8	1.5	1.5	6	moderate_high	glucose-conjugated delivery	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
MRC2	MRC2	Endo180 / uPARAP	collagen internalization receptor	Tier 2: strong receptor candidate	8	1.5	1.5	6	moderate_high	stromal/matrix targeting	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
CEACAM5	CEACAM5	CEA / CEACAM5	carcinoembryonic antigen family	Tier 2: strong receptor candidate	8	0	0	5	high	CEA-targeted ligands	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
KDR	KDR	VEGFR2	angiogenic RTK	Tier 2: strong receptor candidate	7.5	2	2	6	high	VEGFR2-binding peptides	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
ITGB1	ITGB1	Integrin beta 1	integrin / adhesion receptor	Tier 2: strong receptor candidate	7.5	2	2	5	moderate_high	matrix-derived peptides	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
PDGFRB	PDGFRB	PDGFR beta	stromal / vascular RTK receptor	Tier 2: strong receptor candidate	7.5	2	2	5	moderate_high	PDGFR-associated vascular targeting	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
CXCR4	CXCR4	CXCR4	chemokine receptor	Tier 2: strong receptor candidate	7.5	2	2	5	high	CXCR4-targeted ligands	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
PLAUR	PLAUR	uPAR	protease-associated invasion receptor	Tier 2: strong receptor candidate	7.5	1.5	1.5	6	high	uPA/uPAR-binding peptides	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
TEK	TEK	TIE2	angiopoietin receptor / vascular receptor	Tier 2: strong receptor candidate	7.5	0.5	0.5	6	moderate_high	vascular-homing peptides	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
CLDN4	CLDN4	Claudin 4	tight-junction protein	Tier 2: strong receptor candidate	7.5	0.5	0.5	6	moderate_high	claudin-binding ligands	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
ANPEP	ANPEP	CD13 / Aminopeptidase N	vascular-homing / protease receptor	Tier 2: strong receptor candidate	7.5	0.5	0.5	6	very_high	NGR peptides	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.
SLC7A5	SLC7A5	LAT1	amino-acid transporter	Tier 2: strong receptor candidate	7.5	0	0	5	high	amino-acid-mimetic targeting	STRING/PPI support indicates receptor network/module context only; it is not evidence of peptide-receptor binding or nanoparticle targeting.


PDGFRB	PLXNA1	999	SLC7A5 — SLC3A2	9606.ENSP00000264033	9606.ENSP00000275493	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.


EGFR	CBL	999	EGFR — CBL	9606.ENSP00000264033	9606.ENSP00000275493	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGB1	ITGA6	999	ITGB1 — ITGA6	9606.ENSP00000386896	9606.ENSP00000379350	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
NRP1	PLXNA1	999	NRP1 — PLXNA1	9606.ENSP00000265371	9606.ENSP00000377061	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
CD274	CD80	999	CD274 — CD80	9606.ENSP00000264246	9606.ENSP00000370989	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
KDR	VEGFC	999	KDR — VEGFC	9606.ENSP00000263923	9606.ENSP00000480043	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
KDR	VEGFC	999	KDR — VEGFC	9606.ENSP00000480043	9606.ENSP00000263923	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
EGFR	HBEGF	999	EGFR — HBEGF	9606.ENSP00000230990	9606.ENSP00000275493	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
LRP1	APOE	999	LRP1 — APOE	9606.ENSP00000243077	9606.ENSP00000252486	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
EGFR	EREG	999	EGFR — EREG	9606.ENSP00000244869	9606.ENSP00000275493	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
AXL	GAS6	999	AXL — GAS6	9606.ENSP00000301178	9606.ENSP00000331831	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
MET	HGF	999	MET — HGF	9606.ENSP00000222390	9606.ENSP00000317272	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
CD274	PDCD1	999	CD274 — PDCD1	9606.ENSP00000335062	9606.ENSP00000370989	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
TEK	ANGPT2	999	TEK — ANGPT2	9606.ENSP00000314897	9606.ENSP00000369375	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
FLT1	VEGFB	999	FLT1 — VEGFB	9606.ENSP00000311127	9606.ENSP00000282397	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
MET	HGF	999	MET — HGF	9606.ENSP00000317272	9606.ENSP00000222390	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
PLAUR	PLAU	999	PLAUR — PLAU	9606.ENSP00000339328	9606.ENSP00000361850	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGAV	FN1	999	ITGAV — FN1	9606.ENSP00000346839	9606.ENSP00000261023	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGB1	FN1	999	ITGB1 — FN1	9606.ENSP00000346839	9606.ENSP00000379350	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
PLAUR	VTN	999	PLAUR — VTN	9606.ENSP00000339328	9606.ENSP00000226218	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ERBB2	ERBB4	999	ERBB2 — ERBB4	9606.ENSP00000342235	9606.ENSP00000269571	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
FLT1	VEGFB	999	FLT1 — VEGFB	9606.ENSP00000282397	9606.ENSP00000311127	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGB3	ITGA2B	999	ITGB3 — ITGA2B	9606.ENSP00000262407	9606.ENSP00000452786	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
EGFR	EPGN	999	EGFR — EPGN	9606.ENSP00000411898	9606.ENSP00000275493	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGB1	ITGA4	999	ITGB1 — ITGA4	9606.ENSP00000380227	9606.ENSP00000379350	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ERBB2	EGFR	999	ERBB2 — EGFR	9606.ENSP00000269571	9606.ENSP00000275493	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGA5	ITGB1	999	ITGA5 — ITGB1	9606.ENSP00000293379	9606.ENSP00000379350	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
FLT1	PGF	999	FLT1 — PGF	9606.ENSP00000282397	9606.ENSP00000451040	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
CXCR4	CXCL12	999	CXCR4 — CXCL12	9606.ENSP00000386884	9606.ENSP00000379140	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
NRP1	PLXNA2	999	NRP1 — PLXNA2	9606.ENSP00000265371	9606.ENSP00000356000	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
EGFR	EGF	999	EGFR — EGF	9606.ENSP00000265171	9606.ENSP00000275493	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ERBB2	ERBB3	999	ERBB2 — ERBB3	9606.ENSP00000267101	9606.ENSP00000269571	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
EGFR	ERBB3	999	EGFR — ERBB3	9606.ENSP00000267101	9606.ENSP00000275493	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGB3	FN1	999	ITGB3 — FN1	9606.ENSP00000346839	9606.ENSP00000452786	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
CXCR2	CXCL8	999	CXCR2 — CXCL8	9606.ENSP00000306512	9606.ENSP00000319635	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGA5	FN1	999	ITGA5 — FN1	9606.ENSP00000346839	9606.ENSP00000293379	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
AXL	GAS6	999	AXL — GAS6	9606.ENSP00000331831	9606.ENSP00000301178	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
EGFR	TGFA	999	EGFR — TGFA	9606.ENSP00000404131	9606.ENSP00000275493	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ALCAM	CD6	999	ALCAM — CD6	9606.ENSP00000305988	9606.ENSP00000323280	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
TEK	ANGPT2	999	TEK — ANGPT2	9606.ENSP00000369375	9606.ENSP00000314897	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
EGFR	EGF	999	EGFR — EGF	9606.ENSP00000275493	9606.ENSP00000265171	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
PDGFRB	PDGFB	999	PDGFRB — PDGFB	9606.ENSP00000330382	9606.ENSP00000261799	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ALCAM	CD6	999	ALCAM — CD6	9606.ENSP00000323280	9606.ENSP00000305988	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
CXCR2	CXCL8	999	CXCR2 — CXCL8	9606.ENSP00000319635	9606.ENSP00000306512	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
PLAUR	VTN	999	PLAUR — VTN	9606.ENSP00000226218	9606.ENSP00000339328	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
EGFR	TGFA	999	EGFR — TGFA	9606.ENSP00000275493	9606.ENSP00000404131	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
EGFR	EREG	999	EGFR — EREG	9606.ENSP00000275493	9606.ENSP00000244869	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
SLC7A5	SLC3A2	999	SLC7A5 — SLC3A2	9606.ENSP00000261622	9606.ENSP00000367123	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGAV	FN1	999	ITGAV — FN1	9606.ENSP00000261023	9606.ENSP00000346839	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGB1	ILK	999	ITGB1 — ILK	9606.ENSP00000379350	9606.ENSP00000379975	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
TEK	ANGPT1	999	TEK — ANGPT1	9606.ENSP00000428340	9606.ENSP00000369375	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
EGFR	HBEGF	999	EGFR — HBEGF	9606.ENSP00000275493	9606.ENSP00000230990	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
CXCR4	CXCL12	999	CXCR4 — CXCL12	9606.ENSP00000379140	9606.ENSP00000386884	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGB3	ITGAV	999	ITGB3 — ITGAV	9606.ENSP00000452786	9606.ENSP00000261023	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
FLT1	PGF	999	FLT1 — PGF	9606.ENSP00000451040	9606.ENSP00000282397	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGB3	ITGA2B	999	ITGB3 — ITGA2B	9606.ENSP00000452786	9606.ENSP00000262407	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
EGFR	ERBB3	999	EGFR — ERBB3	9606.ENSP00000275493	9606.ENSP00000267101	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
TFRC	HFE	999	TFRC — HFE	9606.ENSP00000376197	9606.ENSP00000417404	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
EGFR	CBL	999	EGFR — CBL	9606.ENSP00000275493	9606.ENSP00000264033	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
EGFR	GRB2	999	EGFR — GRB2	9606.ENSP00000275493	9606.ENSP00000376345	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGB1	ITGA5	999	ITGB1 — ITGA5	9606.ENSP00000379350	9606.ENSP00000293379	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGB3	FN1	999	ITGB3 — FN1	9606.ENSP00000452786	9606.ENSP00000346839	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
EGFR	GRB2	999	EGFR — GRB2	9606.ENSP00000376345	9606.ENSP00000275493	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
EGFR	ERBB2	999	EGFR — ERBB2	9606.ENSP00000275493	9606.ENSP00000269571	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGAV	ITGB3	999	ITGAV — ITGB3	9606.ENSP00000261023	9606.ENSP00000452786	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
EGFR	EPGN	999	EGFR — EPGN	9606.ENSP00000275493	9606.ENSP00000411898	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
NRP1	PLXNA1	999	NRP1 — PLXNA1	9606.ENSP00000377061	9606.ENSP00000265371	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
SLC7A5	SLC3A2	999	SLC7A5 — SLC3A2	9606.ENSP00000367123	9606.ENSP00000261622	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
PLAUR	PLAU	999	PLAUR — PLAU	9606.ENSP00000361850	9606.ENSP00000339328	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
CD274	PDCD1	999	CD274 — PDCD1	9606.ENSP00000370989	9606.ENSP00000335062	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
CD274	CD80	999	CD274 — CD80	9606.ENSP00000370989	9606.ENSP00000264246	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGB1	ITGA4	999	ITGB1 — ITGA4	9606.ENSP00000379350	9606.ENSP00000380227	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
TFRC	HFE	999	TFRC — HFE	9606.ENSP00000417404	9606.ENSP00000376197	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
TEK	ANGPT1	999	TEK — ANGPT1	9606.ENSP00000369375	9606.ENSP00000428340	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
LRP1	APOE	999	LRP1 — APOE	9606.ENSP00000252486	9606.ENSP00000243077	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGB1	ITGA6	999	ITGB1 — ITGA6	9606.ENSP00000379350	9606.ENSP00000386896	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
PDGFRB	PDGFB	999	PDGFRB — PDGFB	9606.ENSP00000261799	9606.ENSP00000330382	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ERBB2	ERBB4	999	ERBB2 — ERBB4	9606.ENSP00000269571	9606.ENSP00000342235	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ERBB2	ERBB3	999	ERBB2 — ERBB3	9606.ENSP00000269571	9606.ENSP00000267101	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGA5	FN1	999	ITGA5 — FN1	9606.ENSP00000293379	9606.ENSP00000346839	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
NRP1	PLXNA2	999	NRP1 — PLXNA2	9606.ENSP00000356000	9606.ENSP00000265371	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGB1	FN1	999	ITGB1 — FN1	9606.ENSP00000379350	9606.ENSP00000346839	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGB1	ILK	999	ITGB1 — ILK	9606.ENSP00000379975	9606.ENSP00000379350	999	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ERBB2	ERBIN	998	ERBB2 — ERBIN	9606.ENSP00000269571	9606.ENSP00000426632	998	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGAV	ITGB6	998	ITGAV — ITGB6	9606.ENSP00000283249	9606.ENSP00000261023	998	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
CD44	SPP1	998	CD44 — SPP1	9606.ENSP00000398632	9606.ENSP00000378517	998	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
EGFR	DCN	998	EGFR — DCN	9606.ENSP00000052754	9606.ENSP00000275493	998	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
DLL3	NOTCH1	998	DLL3 — NOTCH1	9606.ENSP00000205143	9606.ENSP00000498587	998	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
SELE	GLG1	998	SELE — GLG1	9606.ENSP00000205061	9606.ENSP00000331736	998	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
PDGFRA	PDGFB	998	PDGFRA — PDGFB	9606.ENSP00000330382	9606.ENSP00000257290	998	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
SELE	GLG1	998	SELE — GLG1	9606.ENSP00000331736	9606.ENSP00000205061	998	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
CD44	RDX	998	CD44 — RDX	9606.ENSP00000398632	9606.ENSP00000496414	998	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
NRP1	PLXNA3	998	NRP1 — PLXNA3	9606.ENSP00000358696	9606.ENSP00000265371	998	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
VCAM1	ITGB1	998	VCAM1 — ITGB1	9606.ENSP00000294728	9606.ENSP00000379350	998	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
NRP1	PLXNA4	998	NRP1 — PLXNA4	9606.ENSP00000265371	9606.ENSP00000352882	998	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
NRP1	PLXNA3	998	NRP1 — PLXNA3	9606.ENSP00000265371	9606.ENSP00000358696	998	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
VCAM1	ITGA4	998	VCAM1 — ITGA4	9606.ENSP00000294728	9606.ENSP00000380227	998	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
CD44	SPP1	998	CD44 — SPP1	9606.ENSP00000378517	9606.ENSP00000398632	998	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGB1	TLN1	998	ITGB1 — TLN1	9606.ENSP00000379350	9606.ENSP00000316029	998	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
CD44	RDX	998	CD44 — RDX	9606.ENSP00000496414	9606.ENSP00000398632	998	Physical PPI edge context only; not peptide-receptor binding or delivery validation.
ITGAV	ITGB8	998	ITGAV — ITGB8	9606.ENSP00000261023	9606.ENSP00000222573	998	Physical PPI edge context only; not peptide-receptor binding or delivery validation.

Candidate-context explorer

Use Full receptor targetability atlas to inspect HPA-derived receptor–cancer contexts. Use Motif-supported peptide contexts only when you specifically want peptide-to-receptor mappings supported by motif rules or metadata.

Minimum sequence-model score for motif-supported mode

0 1

Minimum candidate-prioritization score for motif-supported mode

0 100

Top receptors, cancers, or candidate rows to display

5 40

Top prioritized contexts

Receptor–cancer evidence heatmap

Batch peptide triage

Upload a CSV or Excel file containing a peptide column named sequence, seq, peptide, or peptide_sequence. The output is intended for computational triage, not experimental confirmation.

Top cancer contexts per peptide

1 10

Batch sequence score vs ligand suitability

Batch triage output

Batch triage output

Model evidence plots

Visual summary of leakage-aware model performance, bioactive hard-negative behavior, and threshold calibration.

Model performance

Bioactive hard-negative challenge

Threshold calibration

Level 1 computational validity

Checks whether model performance reflects reproducible sequence-dependent signal rather than random labels, motif artifacts, or negative-control artifacts.

Permutation control

Motif ablation

Length-stratified AUROC

Negative-type-specific AUROC

Permutation summary

Permutation summary

0.7149	0.5003	0.0139	0.0099	0.6124	0.3351	0.0102	0.0099

Motif-ablation summary

Motif-ablation summary

delta_prob_original_minus_ablated	284	0.8236	0.0924	-0.0383	0.7982	0.8441	0.8835	0.9648

Motif-ablation summary

original_prob	284	0.8236	0.0924	0.4355	0.7982	0.8441	0.8835	0.9648
ablated_prob	284	0.3849	0.1833	0.1415	0.2504	0.3238	0.4806	0.8753
delta_prob_original_minus_ablated	284	0.4387	0.2017	-0.0383	0.2993	0.5105	0.6055	0.7252
original_conservative_prob	284	0.7207	0.0797	0.4167	0.6779	0.7237	0.7707	0.9185
ablated_conservative_prob	284	0.3515	0.1437	0.1407	0.2471	0.3119	0.4342	0.7508
delta_conservative	284	0.3693	0.1607	-0.0454	0.2655	0.4201	0.4969	0.6566

Threshold operating points

Threshold operating points

4202	1401	2801	0.32	0.7149	0.6124	0.5959	0.6387	0.5587	0.2653	0.4393	0.7673	0.5823	0.3683	0.5287	high_precision

Threshold operating points

4202	1401	2801	0.32	0.7149	0.6124	0.5959	0.6387	0.5587	0.2653	0.4393	0.7673	0.5823	0.3683	0.5287	best_F1
4202	1401	2801	0.64	0.7149	0.6124	0.7268	0.6008	0.3521	0.335	0.841	0.2227	0.0883	0.3683	0.5287	best_MCC
4202	1401	2801	0.61	0.7149	0.6124	0.7239	0.6072	0.383	0.3182	0.7516	0.257	0.114	0.3683	0.5287	high_precision

Level 2 external and family-level validation

Strict independent literature-positive validation is constrained because many canonical tumor-homing peptides are already represented in public peptide databases. Family-holdout validation is therefore presented as a pseudo-external generalization stress test.

Leave-family-out validation

Literature case-study metrics

Literature case-study metrics

/content/tumor_homing_peptide_ai/external_validation/external_literature_thps.csv	29	27	0	2	4	0.4811	0.4112	0.4811	0.4229	0.4	0.625	0.5	0.6667	0.625	0.5	0.5	0.5	0.25	0.211	6	2	4	External validation excludes exact primary matches and near-duplicates above configured Tanimoto threshold. This is external-recognition stress testing only.	Validation-suite outputs support computational benchmarking, recognition testing, prioritization, leakage auditing, and plausibility assessment only. They do not validate receptor binding, tumor homing, nanoparticle uptake, biodistribution, therapeutic efficacy, safety, pharmacokinetics, or clinical actionability.

Strict external candidate check

Strict external candidate check

iRGD_variant_CRD	KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK	colorectal tumor vasculature	tumor lymphatics/tumor cells/macrophage context	curated literature tumor-penetrating peptide	31	true	1

Strict external candidate check

iRGD	CRGDKGPDC	RGD/CendR	integrin/NRP tumor-penetrating context	curated literature tumor-penetrating peptide	9	true	1
iRGD_variant_CRD	CRGDKPGDC	RGD/CendR	integrin/NRP tumor-penetrating context	curated iRGD-like sequence	9	true	1
CNGRC	CNGRC	NGR/CD13	CD13/ANPEP tumor vasculature context	curated NGR-family peptide	5	true	1
CREKA	CREKA	ECM/fibrin-fibronectin	tumor-stroma-associated matrix context	curated tumor-stroma-homing peptide	5	true	1
F3	KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK	nucleolin	nucleolin-associated tumor-homing context	curated tumor-homing peptide	31	true	1
GE11	YHWYGYTPQNVI	EGFR	EGFR-targeting context	curated EGFR-targeting peptide	12	true	1
A54	AGKGTPSLETTP	HCC-homing	hepatocellular-carcinoma-binding context	curated HCC-binding peptide	12	true	1
SP94	SFSIIHTPILPL	HCC-homing	hepatocellular-carcinoma-binding context	curated HCC-binding peptide	12	true	1
CGKRK	CGKRK	tumor vasculature	tumor-vasculature-homing context	curated tumor-vasculature peptide	5	true	1
LyP-1	CGNKRTRGC	CendR/p32/NRP-associated	tumor lymphatics/tumor cells/macrophage context	curated LyP-1 sequence	9	true	1
tLyP-1	CGNKRTR	CendR/NRP	truncated LyP-1 tumor-penetrating context	curated tLyP-1 sequence	7	true	1
TT1	CKRGARSTC	p32/gC1qR-associated	p32/gC1qR tumor-homing context	curated TT1 sequence	9	true	1
IF7	IFLLWQR	Annexin A1	tumor vasculature / annexin A1 context	curated IF7 sequence	7	true	1
TMTP1	NVVRQ	metastasis-homing	metastatic tumor-targeting context	curated TMTP1 sequence	5	true	1
p160	VPWMEPAYQRFL	breast/cancer-cell-binding	breast tumor cell-binding context	curated p160 sequence	12	true	1
TCP-1	CTPSPFSHC	colorectal tumor vasculature	colorectal cancer vasculature context	curated TCP-1 sequence	9	true	1

Strict external validation metrics

Strict external validation metrics

Strict external validation metrics are unavailable or no strict external positives remained after overlap filtering.

Family-holdout metrics

Family-holdout metrics

short_cysteine_rich	4048	1247	2801	1387	154	407	307	0	100	0.5932	0.3817	-0.0733	0.3733	0.1818	0.1429	0.5861	0.3725	-0.1158	0.3396	0.1169	0.1429	0.3634	0.3314	0.3099	0.2679

Level 3 biological plausibility checks

Tests whether high-scoring peptide candidates are enriched for known homing-associated motifs and whether prioritized contexts align with receptor/cancer targetability evidence.

Motif enrichment

Targetability plausibility

Top receptor-context consistency

Top receptor-context consistency

ITGAV	CD13 / Aminopeptidase N	1087	86	82.7793	88.9983	63.4147	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)

Top receptor-context consistency

NRP2	Neuropilin 2	59	7	82.7793	88.9983	63.4147	Glioblastoma Multiforme (validation); Skin Cuteneous Melanoma (TCGA); Pancreatic Adenocarcinoma (validation); Thyroid Carcinoma (TCGA); Lung Adenocarcinoma (validation)
NRP1	Neuropilin 1	74	9	82.5869	89.7908	65.9083	Kidney Renal Clear Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (TCGA); Lung Adenocarcinoma (validation); Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation)
ITGAV	Integrin alpha V	1087	86	82.4937	94.8332	70.5101	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)
ITGB5	Integrin beta 5	822	47	81.5971	88.5505	64.0861	Breast Invasive Carcinoma (validation); Pancreatic Adenocarcinoma (TCGA); Pancreatic Adenocarcinoma (validation); Breast Invasive Carcinoma (TCGA); Skin Cuteneous Melanoma (TCGA)
ITGB3	Integrin beta 3	89	27	81.1259	86.1688	58.1669	Thyroid Carcinoma (TCGA); Skin Cuteneous Melanoma (TCGA); Kidney Renal Papillary Cell Carcinoma (TCGA); Kidney Renal Clear Cell Carcinoma (validation); Glioblastoma Multiforme (validation)
ANPEP	CD13 / Aminopeptidase N	15	5	80.3855	82.0766	63.0177	Kidney Renal Papillary Cell Carcinoma (TCGA); Kidney Renal Clear Cell Carcinoma (validation); Liver Hepatocellular Carcinoma (validation); Stomach Adenocarcinoma (TCGA); Liver Hepatocellular Carcinoma (TCGA)

Top cancer-context consistency

Top cancer-context consistency

Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA)	125	91	ITGAV; ITGB5; NRP1; ITGB3; ANPEP	84.7436	94.8332	83.5111

Top cancer-context consistency

Glioblastoma Multiforme (validation)	125	91	ITGAV; ITGB5; NRP2; NRP1; ITGB3	84.7436	94.8332	83.5111
Pancreatic Adenocarcinoma (validation)	122	72	ITGAV; ITGB5; NRP2; NRP1; ITGB3	82.8842	90.9823	74.5823
Breast Invasive Carcinoma (validation)	106	52	ITGAV; ITGB5; NRP1; ITGB3; NRP2	82.5592	88.955	71.439
Lung Squamous Cell Carcinoma (validation)	94	58	ITGAV; ITGB5; NRP1; NRP2	82.4284	89.5222	71.2139
Kidney Renal Clear Cell Carcinoma (validation)	100	59	ITGAV; ITGB5; NRP1; ITGB3; ANPEP	82.3311	89.7908	69.8518
Colon Adenocarcinoma (validation)	79	49	ITGAV; ITGB5; NRP1; NRP2; ITGB3	82.2566	88.6132	68.459
Lung Adenocarcinoma (validation)	81	52	ITGAV; ITGB5; NRP1; NRP2; ITGB3	82.2443	88.8287	68.8153
Rectum Adenocarcinoma (validation)	74	46	ITGAV; ITGB5; NRP1; NRP2; ITGB3	82.1815	88.3377	67.6341
Kidney Renal Clear Cell Carcinoma (TCGA)	83	53	ITGAV; ITGB5; NRP1; ITGB3; NRP2	82.1302	89.5451	68.1072
Glioblastoma Multiforme (TCGA)	61	45	ITGAV; ITGB5; NRP2; NRP1	82.1163	88.0924	67.1086
Pancreatic Adenocarcinoma (TCGA)	82	42	ITGB5; ITGAV; NRP1; NRP2	82.1041	87.7104	68.1007
Breast Invasive Carcinoma (TCGA)	74	38	ITGB5; ITGAV; NRP1; NRP2	82.0189	87.4261	67.0572
Lung Squamous Cell Carcinoma (TCGA)	72	37	ITGAV; ITGB5; NRP2; NRP1	81.9207	87.2154	66.4785
Head and Neck Squamous Cell Carcinoma (TCGA)	73	39	ITGAV; ITGB5; NRP2; NRP1	81.8229	87.3516	66.2268
Thyroid Carcinoma (TCGA)	90	43	ITGAV; ITGB3; ITGB5; NRP2; NRP1	81.8097	87.72	65.4219
Kidney Chromophobe (TCGA)	58	37	ITGAV; ITGB5; NRP1; NRP2; ITGB3	81.7483	87.2209	64.2799
Bladder Urothelial Carcinoma (TCGA)	53	27	ITGB5; ITGAV; NRP1; NRP2	81.6868	86.1721	63.1401
Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA)	50	24	ITGB5; ITGAV; NRP2; NRP1	81.6592	85.852	62.5381
Lung Adenocarcinoma (TCGA)	63	35	ITGAV; ITGB5; NRP1; NRP2; ITGB3	81.6302	86.8278	64.0008
Ovary Serous Cystadenocarcinoma (TCGA)	44	24	ITGB5; ITGAV; NRP2; NRP1	81.6014	85.9392	61.507
Skin Cuteneous Melanoma (TCGA)	82	38	ITGB5; ITGB3; ITGAV; NRP2; NRP1	81.5674	88.6505	63.7618
Ovary Serous Cystadenocarcinoma (validation)	52	27	ITGB5; ITGAV; NRP2; NRP1	81.533	86.208	62.5062
Stomach Adenocarcinoma (TCGA)	52	30	ITGAV; ITGB5; ANPEP; NRP2; NRP1	81.5268	86.2695	62.4522
Liver Hepatocellular Carcinoma (validation)	52	26	ITGAV; ITGB5; ANPEP; NRP1; NRP2	81.4901	85.9693	62.1127
Uterine Corpus Endometrial Carcinoma (TCGA)	41	24	ITGB5; ITGAV; NRP1; NRP2; ITGB3	81.3694	85.5013	59.9281
Kidney Renal Papillary Cell Carcinoma (TCGA)	71	31	ITGAV; ITGB5; ITGB3; ANPEP; NRP1	81.3616	86.9474	61.7809
Rectum Adenocarcinoma (TCGA)	46	24	ITGB5; ITGAV; NRP2; NRP1	81.3599	85.5993	60.9896
Prostate Adenocarcinoma (TCGA)	50	25	ITGAV; ITGB5; NRP1; NRP2; ANPEP	81.291	85.5118	61.2019
Colon Adenocarcinoma (TCGA)	48	24	ITGB5; ITGAV; NRP1; NRP2	81.2553	85.5053	60.9152
Testicular Germ Cell Tumor (TCGA)	36	23	ITGB5; ITGAV; NRP2; NRP1	81.1439	85.3808	59.0715
Liver Hepatocellular Carcinoma (TCGA)	32	18	ITGB5; ITGAV; NRP1; ANPEP; NRP2	80.9488	84.7196	57.1689

Top peptide-candidate consistency

Top peptide-candidate consistency

CRGDCGGKWCFRVCYRGICYRRCRNTACETCTAMID	138	ITGAV; NRP1; NRP2; ITGB5; ITGB3	Glioblastoma Multiforme (validation); Kidney Renal Papillary Cell Carcinoma (TCGA); Pancreatic Adenocarcinoma (validation); Kidney Renal Clear Cell Carcinoma (TCGA); Kidney Renal Clear Cell Carcinoma (validation)	94.8332	85.3382	61.1678

Top peptide-candidate consistency

CRGDK	138	ITGAV; NRP1; NRP2; ITGB5; ITGB3	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (TCGA); Breast Invasive Carcinoma (validation)	94.8332	85.3382	61.1678
CRGDKNTAMID	70	ITGAV; ITGB5; ITGB3	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (TCGA)	92.9117	84.2058	63.7979
RGDLMKLAKNTCTAMID	70	ITGAV; ITGB5; ITGB3	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (TCGA)	92.8582	84.1522	63.7979
CRGDKNT	67	ITGAV; ITGB5; ITGB3	Glioblastoma Multiforme (validation); Kidney Renal Clear Cell Carcinoma (validation); Thyroid Carcinoma (TCGA); Kidney Renal Papillary Cell Carcinoma (TCGA); Skin Cuteneous Melanoma (TCGA)	92.024	83.5221	64.4782
RGDCTAMID	67	ITGAV; ITGB5; ITGB3	Glioblastoma Multiforme (validation); Kidney Renal Clear Cell Carcinoma (validation); Thyroid Carcinoma (TCGA); Kidney Renal Papillary Cell Carcinoma (TCGA); Skin Cuteneous Melanoma (TCGA)	91.9845	83.4827	64.4782
CRGDKPGDCNTCT	65	ITGAV; ITGB5; ITGB3	Thyroid Carcinoma (TCGA); Kidney Renal Papillary Cell Carcinoma (TCGA); Skin Cuteneous Melanoma (TCGA); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	91.6045	83.2248	64.8854
RGDLRELAKNTCTAMID	65	ITGAV; ITGB5; ITGB3	Thyroid Carcinoma (TCGA); Kidney Renal Papillary Cell Carcinoma (TCGA); Skin Cuteneous Melanoma (TCGA); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	91.3081	82.9284	64.8854
CRGDC	65	ITGAV; ITGB5; ITGB3	Thyroid Carcinoma (TCGA); Kidney Renal Papillary Cell Carcinoma (TCGA); Skin Cuteneous Melanoma (TCGA); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	90.9217	82.542	64.8854
CRGDKHADC	65	ITGAV; ITGB5; ITGB3	Thyroid Carcinoma (TCGA); Kidney Renal Papillary Cell Carcinoma (TCGA); Skin Cuteneous Melanoma (TCGA); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	90.9094	82.5297	64.8854
CRGDGWC	65	ITGAV; ITGB5; ITGB3	Thyroid Carcinoma (TCGA); Kidney Renal Papillary Cell Carcinoma (TCGA); Skin Cuteneous Melanoma (TCGA); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	90.811	82.4313	64.8854
CRGDKGPDCNTCT	65	ITGAV; ITGB5; ITGB3	Thyroid Carcinoma (TCGA); Kidney Renal Papillary Cell Carcinoma (TCGA); Skin Cuteneous Melanoma (TCGA); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	90.7594	82.3797	64.8854
CRGDYK	64	ITGB5; ITGAV; ITGB3	Thyroid Carcinoma (TCGA); Kidney Renal Papillary Cell Carcinoma (TCGA); Skin Cuteneous Melanoma (TCGA); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	90.6404	82.3081	65.0433
RGDLADLRKNTCTAMID	63	ITGB5; ITGAV; ITGB3	Thyroid Carcinoma (TCGA); Kidney Renal Papillary Cell Carcinoma (TCGA); Skin Cuteneous Melanoma (TCGA); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	90.4975	82.2114	65.1976
CRGDKPGDCNT	63	ITGB5; ITGAV; ITGB3	Thyroid Carcinoma (TCGA); Kidney Renal Papillary Cell Carcinoma (TCGA); Skin Cuteneous Melanoma (TCGA); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	90.3787	82.0927	65.1976
RGDFKNTCYC	60	ITGB5; ITGAV; ITGB3	Thyroid Carcinoma (TCGA); Skin Cuteneous Melanoma (TCGA); Pancreatic Adenocarcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	89.5753	81.396	65.5531
CRGDCF	60	ITGB5; ITGAV; ITGB3	Thyroid Carcinoma (TCGA); Skin Cuteneous Melanoma (TCGA); Pancreatic Adenocarcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	89.5557	81.3763	65.5531
RGDLLRHVVKILSKYLCTAMID	59	ITGB5; ITGAV; ITGB3	Skin Cuteneous Melanoma (TCGA); Pancreatic Adenocarcinoma (validation); Glioblastoma Multiforme (validation); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	89.4539	81.3093	65.6693
RGDLLRHVVKILEKYLCTAMID	58	ITGAV; ITGB5; ITGB3	Skin Cuteneous Melanoma (TCGA); Glioblastoma Multiforme (validation); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	89.3235	81.2129	65.7824
CRGDKGPDCNT	55	ITGB5; ITGAV; ITGB3	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	89.0207	81.0055	66.1003
CRGDKPGDC	55	ITGB5; ITGAV; ITGB3	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	89.0007	80.9855	66.1003
CRGDCFNT	53	ITGB5; ITGAV; ITGB3	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	88.9487	80.9966	66.3107
CRGDHAGDC	53	ITGB5; ITGAV; ITGB3	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	88.9188	80.9667	66.3107
CRGDSAC	50	ITGAV; ITGB5; ITGB3	Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Breast Invasive Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation); Lung Adenocarcinoma (validation)	88.8064	80.9516	66.6351
RGDCYC	46	ITGAV; ITGB5; ITGB3	Pancreatic Adenocarcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation); Lung Squamous Cell Carcinoma (validation); Breast Invasive Carcinoma (validation); Lung Adenocarcinoma (validation)	88.6984	80.9798	67.0891
RGDFDVCYCCTME	32	ITGAV; ITGB5; ITGB3	Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Breast Invasive Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (TCGA)	88.1146	81.0206	69.1711
RGDPAYNGRFL	32	ITGAV; ITGB5; ANPEP; ITGB3	Kidney Renal Clear Cell Carcinoma (validation); Pancreatic Adenocarcinoma (validation); Breast Invasive Carcinoma (validation); Lung Squamous Cell Carcinoma (validation); Breast Invasive Carcinoma (TCGA)	88.0059	80.9336	69.2433
RPARSGRAGGSVACRGDC	30	ITGAV; ITGB5; ITGB3	Pancreatic Adenocarcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation); Lung Squamous Cell Carcinoma (validation); Breast Invasive Carcinoma (validation); Pancreatic Adenocarcinoma (TCGA)	87.9973	81.0151	69.5435
RGDKLAK	40	ITGAV; NRP1; ITGB5; NRP2	Pancreatic Adenocarcinoma (validation); Glioblastoma Multiforme (validation); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (TCGA)	87.8663	80.9845	69.8783
CGKRGDSIC	26	ITGAV; ITGB5	Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Lung Squamous Cell Carcinoma (TCGA); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	87.8626	81.1336	70.3877
CRGDKGPD	26	ITGAV; ITGB5	Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Lung Squamous Cell Carcinoma (TCGA); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	87.7851	81.0561	70.3877
RGDKCT	25	ITGAV; ITGB5	Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Lung Squamous Cell Carcinoma (TCGA); Breast Invasive Carcinoma (validation); Breast Invasive Carcinoma (TCGA)	87.733	81.0731	70.618
CRGDKTTNC	25	ITGAV; ITGB5	Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Lung Squamous Cell Carcinoma (TCGA); Breast Invasive Carcinoma (validation); Breast Invasive Carcinoma (TCGA)	87.732	81.072	70.618
CRGDHGVEC	24	ITGAV; ITGB5	Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Lung Squamous Cell Carcinoma (TCGA); Breast Invasive Carcinoma (validation); Breast Invasive Carcinoma (TCGA)	87.6037	81.0151	70.8558
KCRGDPLGVRGY	20	ITGAV; ITGB5	Pancreatic Adenocarcinoma (validation); Breast Invasive Carcinoma (validation); Breast Invasive Carcinoma (TCGA); Pancreatic Adenocarcinoma (TCGA); Kidney Renal Clear Cell Carcinoma (validation)	87.2619	80.9711	71.8482
RGDFKCYC	19	ITGAV; ITGB5	Pancreatic Adenocarcinoma (validation); Breast Invasive Carcinoma (validation); Pancreatic Adenocarcinoma (TCGA); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation)	87.1411	80.937	72.1372
CRGDKGPDC	19	ITGAV; ITGB5	Pancreatic Adenocarcinoma (validation); Breast Invasive Carcinoma (validation); Pancreatic Adenocarcinoma (TCGA); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation)	87.139	80.9349	72.1372
CRGDKGPDCCYC	19	ITGAV; ITGB5	Pancreatic Adenocarcinoma (validation); Breast Invasive Carcinoma (validation); Pancreatic Adenocarcinoma (TCGA); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation)	87.1201	80.9159	72.1372
CRGDRGPDCNT	16	ITGAV; ITGB5	Pancreatic Adenocarcinoma (validation); Breast Invasive Carcinoma (validation); Glioblastoma Multiforme (validation); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation)	86.8005	80.8556	73.0012
CRGDAGINC	14	ITGAV; ITGB5	Pancreatic Adenocarcinoma (validation); Breast Invasive Carcinoma (validation); Lung Squamous Cell Carcinoma (validation); Glioblastoma Multiforme (validation); Kidney Renal Clear Cell Carcinoma (validation)	86.672	80.9413	73.7152
RGDFNTCT	14	ITGAV; ITGB5	Pancreatic Adenocarcinoma (validation); Breast Invasive Carcinoma (validation); Lung Squamous Cell Carcinoma (validation); Glioblastoma Multiforme (validation); Kidney Renal Clear Cell Carcinoma (validation)	86.626	80.8952	73.7152
CRGDKGPEC	14	ITGAV; ITGB5	Pancreatic Adenocarcinoma (validation); Breast Invasive Carcinoma (validation); Lung Squamous Cell Carcinoma (validation); Glioblastoma Multiforme (validation); Kidney Renal Clear Cell Carcinoma (validation)	86.5999	80.8692	73.7152
ACDCRGDCFCG	11	ITGAV; ITGB5	Breast Invasive Carcinoma (validation); Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation)	86.4039	81.0594	75.0026
CRGDKRGPDEC	11	ITGAV; ITGB5	Breast Invasive Carcinoma (validation); Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation)	86.1793	80.8348	75.0026
CEKRGDSVC	11	ITGAV; ITGB5	Breast Invasive Carcinoma (validation); Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation)	86.0802	80.7357	75.0026
CGRGDMPSC	10	ITGAV; ITGB5	Breast Invasive Carcinoma (validation); Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation)	85.8011	80.5962	75.468
CDCRGDCFC	8	ITGAV; ITGB5	Breast Invasive Carcinoma (validation); Pancreatic Adenocarcinoma (validation); Glioblastoma Multiforme (validation); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation)	85.6486	80.761	76.5256
RGDGWK	8	ITGAV; ITGB5	Breast Invasive Carcinoma (validation); Pancreatic Adenocarcinoma (validation); Glioblastoma Multiforme (validation); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation)	85.6445	80.7569	76.5256
CTGRGDALC	6	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	85.4581	81.025	78.0408
RVCFLWQDGRCVF	6	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	85.4058	80.9727	78.0408
GRGDSPK	5	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation); Breast Invasive Carcinoma (validation)	85.204	81.0852	79.0884
CGRGDSPDC	4	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation)	84.9877	81.3087	80.5546
CRGDKGENC	3	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation)	84.8398	81.7859	82.638
CRGDHAANC	3	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation)	84.837	81.783	82.638
CEKRGDNLC	3	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation)	84.8175	81.7636	82.638
CGDGRG	3	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation)	84.8076	81.7537	82.638
CRGDCGGKWCFRVCYRGICYRRCRNTACETCTAMID	3	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Lung Squamous Cell Carcinoma (validation)	84.7996	81.7457	82.638
RGDLMKLAK	5	ITGAV; NRP1	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation); Kidney Renal Clear Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (TCGA); Lung Squamous Cell Carcinoma (validation)	84.6722	80.7737	79.8229
CRGDRCPDC	2	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation)	84.3545	82.4291	86.3997
CRGDKGPDCCT	2	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation)	84.3421	82.4167	86.3997
CRGDRGPDC	2	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation)	84.3053	82.3799	86.3997
GACRGDCLGA	2	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation)	84.2936	82.3682	86.3997
RGDYKCYC	2	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation)	84.2167	82.2913	86.3997
RGDK	2	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation)	84.0509	82.1254	86.3997
GGCRGDMFGCNT	2	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation)	84.0038	82.0784	86.3997
CSGRGDSLC	2	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation)	83.995	82.0696	86.3997
CNGRCKHKHK	30	NRP1; NRP2; ANPEP	Kidney Renal Clear Cell Carcinoma (validation); Glioblastoma Multiforme (validation); Lung Squamous Cell Carcinoma (validation); Lung Adenocarcinoma (validation); Pancreatic Adenocarcinoma (validation)	83.9537	80.8253	65.5818
GGCRGDMFGC	2	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation)	83.8596	81.9342	86.3997
CGRGDNLPC	2	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation)	83.5627	81.6373	86.3997
RGDFK	2	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation)	83.4501	81.5247	86.3997
RGDFC	2	ITGAV	Glioblastoma Multiforme (validation); Pancreatic Adenocarcinoma (validation)	83.3501	81.4247	86.3997
CCGPDGRDGRDGRDGR	1	ITGAV	Glioblastoma Multiforme (validation)	82.8259	82.8259	92.8177
CRGDCGGKWCFRVCYRGICYRRCR	1	ITGAV	Glioblastoma Multiforme (validation)	82.7552	82.7552	92.8177
CQSCNGRCVR	14	NRP1; NRP2; ANPEP	Glioblastoma Multiforme (validation); Kidney Renal Papillary Cell Carcinoma (TCGA); Pancreatic Adenocarcinoma (validation); Kidney Renal Clear Cell Carcinoma (TCGA); Kidney Renal Clear Cell Carcinoma (validation)	82.7505	80.6492	69.0056
CEKRGDSLC	1	ITGAV	Glioblastoma Multiforme (validation)	82.5528	82.5528	92.8177
CWRGDRKIC	1	ITGAV	Glioblastoma Multiforme (validation)	82.5078	82.5078	92.8177
RGDYC	1	ITGAV	Glioblastoma Multiforme (validation)	82.454	82.454	92.8177
CRGDDGPDC	1	ITGAV	Glioblastoma Multiforme (validation)	82.3819	82.3819	92.8177
CGRGDNLAC	1	ITGAV	Glioblastoma Multiforme (validation)	82.274	82.274	92.8177
KNGRECYC	7	ANPEP	Kidney Renal Papillary Cell Carcinoma (TCGA); Kidney Renal Clear Cell Carcinoma (validation); Liver Hepatocellular Carcinoma (validation); Stomach Adenocarcinoma (TCGA); Liver Hepatocellular Carcinoma (TCGA)	82.0766	80.9856	61.6621
RGDFCCYC	1	ITGAV	Glioblastoma Multiforme (validation)	81.8575	81.8575	92.8177
RGD	1	ITGAV	Glioblastoma Multiforme (validation)	81.7211	81.7211	92.8177
CPTCNGRCVR	7	NRP1; NRP2	Glioblastoma Multiforme (validation); Kidney Renal Clear Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (TCGA); Skin Cuteneous Melanoma (TCGA); Lung Adenocarcinoma (validation)	81.6817	80.5326	72.1794
RGDPAYQGRFLNT	1	ITGAV	Glioblastoma Multiforme (validation)	81.4708	81.4708	92.8177
CPLCNGRCAR	4	NRP1; NRP2	Kidney Renal Clear Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (TCGA); Glioblastoma Multiforme (validation); Skin Cuteneous Melanoma (TCGA)	81.1669	80.6223	74.1944
CWLCNGRCGR	4	NRP1; NRP2	Kidney Renal Clear Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (TCGA); Glioblastoma Multiforme (validation); Skin Cuteneous Melanoma (TCGA)	81.1629	80.6183	74.1944
RGDV	1	ITGAV	Glioblastoma Multiforme (validation)	80.4657	80.4657	92.8177
RGDLLRHVVKILEKYL	1	ITGAV	Glioblastoma Multiforme (validation)	80.4339	80.4339	92.8177
RGDFDKCYC	1	ITGAV	Glioblastoma Multiforme (validation)	80.4178	80.4178	92.8177
CGKRK	2	NRP1	Kidney Renal Clear Cell Carcinoma (validation); Kidney Renal Clear Cell Carcinoma (TCGA)	79.9767	79.8538	75.6002
RGDPAYQGRFL	1	ITGAV	Glioblastoma Multiforme (validation)	79.8977	79.8977	92.8177
RGDYK	1	ITGAV	Glioblastoma Multiforme (validation)	79.8207	79.8207	92.8177
RGDYCCYC	1	ITGAV	Glioblastoma Multiforme (validation)	79.6841	79.6841	92.8177
RGDLLRHVVKILSKYL	1	ITGAV	Glioblastoma Multiforme (validation)	79.5644	79.5644	92.8177
CNGRCVSGCAGRC	1	ANPEP	Kidney Renal Papillary Cell Carcinoma (TCGA)	79.5125	79.5125	65.2988

Top 100 recommendations

Top 100 recommendations

RGDLLRHVVKILSKYLCTAMID	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Kidney Renal Clear Cell Carcinoma (validation)	0.9397	0.8749	0.9411	0.8116	98	92.8177	94.8332	88.3437	90.2923	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.

Top 100 recommendations

CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.9397	0.8749	0.9411	0.8116	98	92.8177	94.8332	92.507	90.2923	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKNTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.9367	0.8074	0.9568	0.6739	92	92.8177	92.9117	88.3437	83.6725	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDLMKLAKNTCTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.9353	0.7862	0.9572	0.6346	92	92.8177	92.8582	87.6039	82.2956	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKNT	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.9145	0.8382	0.9213	0.7645	92	92.8177	92.024	89.424	86.8441	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDCTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.9435	0.8082	0.9646	0.6654	88	92.8177	91.9845	87.1748	82.1756	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKPGDCNTCT	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.904	0.7485	0.9259	0.5876	92	92.8177	91.6045	86.2842	80.6537	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDLRELAKNTCTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8966	0.706	0.9156	0.5126	92	92.8177	91.3081	84.7957	78.0272	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Pancreatic Adenocarcinoma (validation)	0.9397	0.8749	0.9411	0.8116	98	79.9816	90.9823	88.0143	85.7997	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDC	RGD/integrin-like; cysteine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.9169	0.8458	0.9226	0.7743	88	92.8177	90.9217	88.4892	85.9868	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKHADC	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8866	0.8124	0.858	0.7339	92	92.8177	90.9094	88.5202	85.7731	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDGWC	RGD/integrin-like; cysteine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.9141	0.8151	0.9314	0.7201	88	92.8177	90.811	87.4153	84.0914	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKGPDCNTCT	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8829	0.714	0.8969	0.5364	92	92.8177	90.7594	85.0748	78.8596	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDYK	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8799	0.7903	0.8754	0.7008	92	92.8177	90.6404	87.748	84.6133	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDLADLRKNTCTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8763	0.6768	0.8979	0.4738	92	92.8177	90.4975	83.7738	76.6679	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKPGDCNT	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8733	0.7365	0.8837	0.5931	92	92.8177	90.3787	85.8632	80.8459	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	NRP1	Neuropilin 1	Kidney Renal Clear Cell Carcinoma (validation)	0.9397	0.8749	0.9411	0.8116	98	76.0097	89.7908	86.6242	84.4095	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDFKNTCYC	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8533	0.7214	0.8626	0.596	92	92.8177	89.5753	85.3364	80.9479	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDCF	RGD/integrin-like; cysteine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8828	0.8042	0.8753	0.7253	88	92.8177	89.5557	87.0348	84.271	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	NRP1	Neuropilin 1	Kidney Renal Clear Cell Carcinoma (TCGA)	0.9397	0.8749	0.9411	0.8116	98	75.1907	89.5451	86.3375	84.1229	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Lung Squamous Cell Carcinoma (validation)	0.9397	0.8749	0.9411	0.8116	98	75.1146	89.5222	86.3109	84.0962	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDLLRHVVKILSKYLCTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.9027	0.7626	0.9065	0.6185	85	92.8177	89.4539	84.6759	79.6327	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDLLRHVVKILEKYLCTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8995	0.7598	0.8987	0.6165	85	92.8177	89.3235	84.5789	79.5638	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Kidney Renal Clear Cell Carcinoma (validation)	0.9397	0.8749	0.9411	0.8116	98	74.3045	89.2792	86.0273	83.8127	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKNTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Pancreatic Adenocarcinoma (validation)	0.9367	0.8074	0.9568	0.6739	92	79.9816	89.0609	83.8511	79.1798	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKGPDCNT	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8394	0.6895	0.8359	0.5293	92	92.8177	89.0207	84.2198	78.6108	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDLMKLAKNTCTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Pancreatic Adenocarcinoma (validation)	0.9353	0.7862	0.9572	0.6346	92	79.9816	89.0074	83.1113	77.803	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKPGDC	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8389	0.7171	0.8211	0.5896	92	92.8177	89.0007	85.1836	80.7231	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	NRP2	Neuropilin 2	Glioblastoma Multiforme (validation)	0.9397	0.8749	0.9411	0.8116	98	73.3682	88.9983	85.6996	83.485	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Breast Invasive Carcinoma (validation)	0.9397	0.8749	0.9411	0.8116	98	73.2237	88.955	85.6491	83.4344	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDCFNT	RGD/integrin-like; cysteine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8676	0.7712	0.8659	0.6741	88	92.8177	88.9487	85.8793	82.481	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDHAGDC	RGD/integrin-like; cysteine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8668	0.7658	0.8502	0.6632	88	92.8177	88.9188	85.6896	82.0992	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Lung Adenocarcinoma (validation)	0.9397	0.8749	0.9411	0.8116	98	72.8029	88.8287	85.5018	83.2871	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDSAC	RGD/integrin-like; cysteine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.864	0.7575	0.863	0.6537	88	92.8177	88.8064	85.3979	81.7657	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDCYC	RGD/integrin-like; cysteine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8613	0.7544	0.8764	0.6538	88	92.8177	88.6984	85.2885	81.7677	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	NRP2	Neuropilin 2	Skin Cuteneous Melanoma (TCGA)	0.9397	0.8749	0.9411	0.8116	98	72.2089	88.6505	85.2939	83.0792	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Colon Adenocarcinoma (validation)	0.9397	0.8749	0.9411	0.8116	98	72.0845	88.6132	85.2504	83.0357	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGB5	Integrin beta 5	Breast Invasive Carcinoma (validation)	0.9397	0.8749	0.9411	0.8116	98	71.8755	88.5505	85.1772	82.9626	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Kidney Renal Clear Cell Carcinoma (TCGA)	0.9397	0.8749	0.9411	0.8116	98	71.3089	88.3805	84.9789	82.7642	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Rectum Adenocarcinoma (validation)	0.9397	0.8749	0.9411	0.8116	98	71.1662	88.3377	84.929	82.7143	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKNT	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Pancreatic Adenocarcinoma (validation)	0.9145	0.8382	0.9213	0.7645	92	79.9816	88.1732	84.9314	82.3515	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDCTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Pancreatic Adenocarcinoma (validation)	0.9435	0.8082	0.9646	0.6654	88	79.9816	88.1337	82.6821	77.683	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDFDVCYCCTME	RGD/integrin-like; cysteine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8467	0.7143	0.8211	0.581	88	92.8177	88.1146	83.8871	79.22	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (TCGA)	0.9397	0.8749	0.9411	0.8116	98	70.3486	88.0924	84.6428	82.4281	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDPAYNGRFL	RGD/integrin-like; NGR/CD13-like	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.829	0.7312	0.7924	0.6265	90	92.8177	88.0059	85.0766	81.414	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RPARSGRAGGSVACRGDC	RGD/integrin-like; cysteine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8438	0.737	0.8045	0.6309	88	92.8177	87.9973	84.6805	80.9694	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	NRP1	Neuropilin 1	Lung Adenocarcinoma (validation)	0.9397	0.8749	0.9411	0.8116	98	69.7341	87.9081	84.4277	82.2131	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDKLAK	RGD/integrin-like; CendR-like C-terminal motif; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8255	0.7073	0.8049	0.584	90	92.8177	87.8663	84.2428	79.9267	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CGKRGDSIC	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8104	0.7081	0.7707	0.6025	92	92.8177	87.8626	84.8702	81.1742	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	NRP2	Neuropilin 2	Pancreatic Adenocarcinoma (validation)	0.9397	0.8749	0.9411	0.8116	98	69.5637	87.857	84.3681	82.1534	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKGPD	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8085	0.6775	0.7771	0.5378	92	92.8177	87.7851	83.799	78.9097	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKPGDCNTCT	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Pancreatic Adenocarcinoma (validation)	0.904	0.7485	0.9259	0.5876	92	79.9816	87.7537	81.7915	76.1611	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	NRP1	Neuropilin 1	Glioblastoma Multiforme (validation)	0.9397	0.8749	0.9411	0.8116	98	69.1802	87.7419	84.2338	82.0192	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDKCT	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8072	0.6974	0.8245	0.5914	92	92.8177	87.733	84.494	80.7838	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKTTNC	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8072	0.6961	0.7607	0.5814	92	92.8177	87.732	84.4507	80.4365	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Thyroid Carcinoma (TCGA)	0.9397	0.8749	0.9411	0.8116	98	69.1071	87.72	84.2083	81.9936	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGB5	Integrin beta 5	Pancreatic Adenocarcinoma (TCGA)	0.9397	0.8749	0.9411	0.8116	98	69.0752	87.7104	84.1971	81.9825	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGB5	Integrin beta 5	Pancreatic Adenocarcinoma (validation)	0.9397	0.8749	0.9411	0.8116	98	68.8011	87.6282	84.1012	81.8865	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDHGVEC	RGD/integrin-like; cysteine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.834	0.7103	0.8152	0.5788	88	92.8177	87.6037	83.7483	79.1452	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKNTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Lung Squamous Cell Carcinoma (validation)	0.9367	0.8074	0.9568	0.6739	92	75.1146	87.6008	82.1477	77.4764	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDLMKLAKNTCTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Lung Squamous Cell Carcinoma (validation)	0.9353	0.7862	0.9572	0.6346	92	75.1146	87.5473	81.4078	76.0995	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDLRELAKNTCTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Pancreatic Adenocarcinoma (validation)	0.8966	0.706	0.9156	0.5126	92	79.9816	87.4573	80.3031	73.5346	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGB5	Integrin beta 5	Breast Invasive Carcinoma (TCGA)	0.9397	0.8749	0.9411	0.8116	98	68.1276	87.4261	83.8654	81.6508	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKNTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Kidney Renal Clear Cell Carcinoma (validation)	0.9367	0.8074	0.9568	0.6739	92	74.3045	87.3577	81.8641	77.1928	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Head and Neck Squamous Cell Carcinoma (TCGA)	0.9397	0.8749	0.9411	0.8116	98	67.8791	87.3516	83.7785	81.5638	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDLMKLAKNTCTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Kidney Renal Clear Cell Carcinoma (validation)	0.9353	0.7862	0.9572	0.6346	92	74.3045	87.3042	81.1243	75.8159	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Pancreatic Adenocarcinoma (TCGA)	0.9397	0.8749	0.9411	0.8116	98	67.7193	87.3036	83.7225	81.5079	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
KCRGDPLGVRGY	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.7954	0.6571	0.7965	0.5238	92	92.8177	87.2619	83.0833	78.4195	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Kidney Chromophobe (TCGA)	0.9397	0.8749	0.9411	0.8116	98	67.4435	87.2209	83.626	81.4113	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Lung Squamous Cell Carcinoma (TCGA)	0.9397	0.8749	0.9411	0.8116	98	67.4253	87.2154	83.6196	81.405	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDFKCYC	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.7924	0.6807	0.7875	0.5732	92	92.8177	87.1411	83.9102	80.1469	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKGPDC	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.7923	0.6626	0.755	0.5226	92	92.8177	87.139	83.2758	78.3761	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKGPDCCYC	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.7919	0.631	0.7544	0.4647	92	92.8177	87.1201	82.1724	76.3504	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	NRP2	Neuropilin 2	Thyroid Carcinoma (TCGA)	0.9397	0.8749	0.9411	0.8116	98	67.0279	87.0962	83.4805	81.2659	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDC	RGD/integrin-like; cysteine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Pancreatic Adenocarcinoma (validation)	0.9169	0.8458	0.9226	0.7743	88	79.9816	87.0709	83.9966	81.4941	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKHADC	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Pancreatic Adenocarcinoma (validation)	0.8866	0.8124	0.858	0.7339	92	79.9816	87.0585	84.0275	81.2805	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	NRP1	Neuropilin 1	Pancreatic Adenocarcinoma (validation)	0.9397	0.8749	0.9411	0.8116	98	66.8944	87.0562	83.4338	81.2192	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKNTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Breast Invasive Carcinoma (validation)	0.9367	0.8074	0.9568	0.6739	92	73.2237	87.0335	81.4858	76.8146	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDLMKLAKNTCTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Breast Invasive Carcinoma (validation)	0.9353	0.7862	0.9572	0.6346	92	73.2237	86.98	80.746	75.4377	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDGWC	RGD/integrin-like; cysteine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Pancreatic Adenocarcinoma (validation)	0.9141	0.8151	0.9314	0.7201	88	79.9816	86.9602	82.9226	79.5987	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	NRP1	Neuropilin 1	Kidney Renal Papillary Cell Carcinoma (TCGA)	0.9397	0.8749	0.9411	0.8116	98	66.532	86.9474	83.307	81.0923	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKGPDCNTCT	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Pancreatic Adenocarcinoma (validation)	0.8829	0.714	0.8969	0.5364	92	79.9816	86.9086	80.5822	74.367	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKNTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Lung Adenocarcinoma (validation)	0.9367	0.8074	0.9568	0.6739	92	72.8029	86.9073	81.3385	76.6673	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Breast Invasive Carcinoma (TCGA)	0.9397	0.8749	0.9411	0.8116	98	66.3572	86.895	83.2458	81.0311	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDLMKLAKNTCTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Lung Adenocarcinoma (validation)	0.9353	0.7862	0.9572	0.6346	92	72.8029	86.8537	80.5987	75.2904	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Lung Adenocarcinoma (TCGA)	0.9397	0.8749	0.9411	0.8116	98	66.1331	86.8278	83.1674	80.9527	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGB5	Integrin beta 5	Skin Cuteneous Melanoma (TCGA)	0.9397	0.8749	0.9411	0.8116	98	66.0982	86.8173	83.1552	80.9405	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDRGPDCNT	RGD/integrin-like; cysteine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8139	0.678	0.82	0.5362	88	92.8177	86.8005	82.6173	77.652	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDYK	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Pancreatic Adenocarcinoma (validation)	0.8799	0.7903	0.8754	0.7008	92	79.9816	86.7896	83.2554	80.1207	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGB5	Integrin beta 5	Lung Squamous Cell Carcinoma (TCGA)	0.9397	0.8749	0.9411	0.8116	98	65.9322	86.7675	83.097	80.8824	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKNT	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Lung Squamous Cell Carcinoma (validation)	0.9145	0.8382	0.9213	0.7645	92	75.1146	86.7131	83.2279	80.648	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKNTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Colon Adenocarcinoma (validation)	0.9367	0.8074	0.9568	0.6739	92	72.0845	86.6918	81.0871	76.4159	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDCTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Lung Squamous Cell Carcinoma (validation)	0.9435	0.8082	0.9646	0.6654	88	75.1146	86.6736	80.9787	75.9795	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDAGINC	RGD/integrin-like; cysteine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8107	0.7272	0.7577	0.6428	88	92.8177	86.672	84.3396	81.3844	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDLADLRKNTCTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Pancreatic Adenocarcinoma (validation)	0.8763	0.6768	0.8979	0.4738	92	79.9816	86.6467	79.2812	72.1752	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDLMKLAKNTCTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Colon Adenocarcinoma (validation)	0.9353	0.7862	0.9572	0.6346	92	72.0845	86.6382	80.3473	75.039	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKNTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGB5	Integrin beta 5	Breast Invasive Carcinoma (validation)	0.9367	0.8074	0.9568	0.6739	92	71.8755	86.6291	81.014	76.3427	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDFNTCT	RGD/integrin-like; cysteine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.8095	0.6544	0.838	0.5021	88	92.8177	86.626	81.7899	76.4585	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDK	RGD/integrin-like; CendR-like C-terminal motif; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGB5	Integrin beta 5	Lung Squamous Cell Carcinoma (validation)	0.9397	0.8749	0.9411	0.8116	98	65.4101	86.6109	82.9143	80.6997	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
CRGDKGPEC	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGAV	Integrin alpha V	Glioblastoma Multiforme (validation)	0.7789	0.615	0.7485	0.4412	92	92.8177	86.5999	81.6104	75.5288	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.
RGDLMKLAKNTCTAMID	RGD/integrin-like; cysteine-containing/conjugation-compatible; lysine-containing/conjugation-compatible	ITGB5	Integrin beta 5	Breast Invasive Carcinoma (validation)	0.9353	0.7862	0.9572	0.6346	92	71.8755	86.5755	80.2741	74.9658	motif-supported receptor-context match	Computational triage recommendation only. This score combines database-positive THP status, available model prediction evidence, heuristic ligand suitability, conservative motif/metadata receptor inference, and HPA+STRING receptor-cancer contextual targetability. It does not demonstrate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological validation.	OOF recommendation score is a computational triage score combining cluster-aware cross-fitted k-mer model probability, heuristic ligand suitability, and HPA+STRING receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.	Ensemble recommendation score is a computational triage score combining cluster-aware ensemble prediction, ligand suitability, and receptor-cancer contextual targetability. It does not validate peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, or biological activity.

Scope and evidence boundaries

THP-NanoTarget is a computational triage and hypothesis-generation framework. It is not an experimental validation platform and should not be interpreted as evidence of binding, delivery, or efficacy.

Why the full atlas view shows more receptors

The dashboard has two visualization modes:

Mode	Data source	Meaning
Full receptor targetability atlas	HPA-derived receptor targetability table	Shows all receptor–cancer targetability pairs available in the receptor atlas
Motif-supported peptide contexts	Candidate-context matrix	Shows only receptors supported by peptide motifs or metadata

If the motif-supported view shows mostly ITGAV, ITGB3, and ANPEP, that is expected because the current receptor-mapping rules map RGD/DGR motifs to integrins and NGR/CNGR motifs to ANPEP/CD13.

Evidence boundaries

This tool does not prove receptor binding, nanoparticle uptake, tumor selectivity, pharmacokinetics, safety, therapeutic efficacy, or clinical relevance.

The appropriate use is computational triage, candidate triage, analog exploration, and hypothesis generation for future experimental validation.

Protein-interaction network layer

The Protein Interaction Network tab uses STRING physical protein-protein interaction outputs from the HPA+STRING receptor-prioritization workflow. This layer supports receptor network/module context and receptor-priority interpretation only. It must not be described as peptide-receptor binding, nanoparticle uptake, biodistribution, therapeutic efficacy, safety, or clinical actionability.

Conservative analog generator

The analog-generation tab creates motif-aware THP-like sequence analogs from user-supplied seed peptides. It ranks candidates using model score, motif-rule score, RDKit descriptor plausibility, nearest-positive novelty audit, and hard-negative similarity checks.

Generated analogs should be described as computational THP-like analog candidates, not as newly discovered or experimentally validated tumor-homing peptides.

THP-NanoTarget | Public-data peptide cheminformatics and computational triage tool | Developed by Ashutosh Tiwari, Taipei Medical University | Research use only | Requires experimental validation

Built with Gradio logo


RGD_integrin	4048	1247	2801	561	154	407	307	100	0.5932	0.3817	0.087	0.3733	0.1818	0.1429	0.5861	0.3725	0.0471	0.3396	0.1169	0.1429	0.3634	0.308	0.3099	0.2679
CendR_like	4117	1316	2801	352	85	267	167	100	0.762	0.5791	0.3641	0.5114	0.5294	0.4118	0.7674	0.5922	0.4366	0.6269	0.4941	0.4941	0.5309	0.337	0.5359	0.2976
NGR_CD13	4142	1341	2801	278	60	218	118	100	0.5861	0.2537	-0.0733	0.1489	0.1167	0.05	0.5533	0.2375	-0.1158	0.0882	0.05	0.0333	0.3545	0.3314	0.3262	0.2902
short_cysteine_rich	3773	972	2801	1387	429	958	858	100	0.7409	0.583	0.2825	0.7188	0.2145	0.3636	0.7345	0.5754	0.2543	0.7556	0.1585	0.3473	0.357	0.2215	0.2903	0.1876
short_cationic	4034	1233	2801	599	168	431	331	100	0.6401	0.4546	0.2391	0.5326	0.2917	0.2917	0.6423	0.455	0.227	0.5806	0.2143	0.2857	0.383	0.2917	0.3428	0.2568